stockrowCelldex Therapeutics, Inc.
CLDX Healthcare Biotechnology
Celldex Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.5 million, down 78.0% from fiscal 2024.
- Revenue
- −96.8%
- EPS
- −10.6%
- Free cash flow
- −35.5%
Quarter to June 2026, against a year earlier
Follow CLDX
Alert me
Celldex Therapeutics, Inc. (CLDX) Current ratio
Celldex Therapeutics, Inc.'s current ratio at the end of the quarter to 30 June 2026 was 11.8×, up 1.3× from fiscal 2025 (10.5×). Over the past ten years it has ranged from 5.2× (fiscal 2017) to 24.9× (fiscal 2021); the current reading is higher than 55% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 10.5× | (44.56%) |
| FY2024 | 18.9× | 36.38% |
| FY2023 | 13.9× | (18.75%) |
| FY2022 | 17.1× | (31.32%) |
| FY2021 | 24.9× | 78.49% |
| FY2020 | 13.9× | 143.11% |
| FY2019 | 5.7× | (27.14%) |
| FY2018 | 7.9× | 50.64% |
| FY2017 | 5.2× | (6.00%) |
| FY2016 | 5.6× | (43.07%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Jun 2026 | 11.8× | 32.50% |
| Mar 2026 | 8.9× | (14.91%) |
| Dec 2025 | 10.5× | (19.38%) |
| Sep 2025 | 13.0× | (33.88%) |
| 42 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| PVLA Palvella Therapeutics, Inc. compare | 21.2× |
| IMNM Immunome, Inc. compare | 15.1× |
| PHVS Pharvaris N.V. compare | 11.9× |
| CLDX Celldex Therapeutics, Inc. | 11.8× |
| VERA Vera Therapeutics, Inc. compare | 10.9× |
| AUPH Aurinia Pharmaceuticals Inc compare | 6.1× |
| ADMA ADMA Biologics Inc compare | 6.0× |
| VCEL Vericel Corporation compare | 5.1× |
| BHVN Biohaven Ltd. compare | 3.1× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on CLDX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement